Nebulized Resveratrol Plus Carboxymethyl-β-Glucan for Reducing IL-5 in Children With Allergic Rhinitis
Status:
Completed
Trial end date:
2018-07-31
Target enrollment:
Participant gender:
Summary
Single-center, randomized, placebo-controlled study to:
- characterize the subjects at baseline and discriminate groups of children based on IL-5,
IL-17, IL-23 and INF-γ;
- investigate the effect of Resveratrol plus Carboxymethyl-β-Glucan, two sprays
(100µL/spray) for nostril three times/day for 4 weeks, in comparison with placebo, in
reducing nasal interleukin-5 (IL-5) in children with Allergic Rhinitis (AR).
Secondary objectives are to examine the effect of resveratrol plus carboxymethyl-β-glucan, in
comparison with placebo, on subjective parameters, i.e. symptom scores, visual analogue
scales for rhinitis, quality of life and quality of sleep, and the effect on objective
parameters, i.e. nasal nitric oxide (nNO) levels, nasal cytology and acoustic rhinometry.
Phase:
Phase 4
Details
Lead Sponsor:
Istituto di Biomedicina e Immunologia Molecolare Alberto Monroy Istituto per la Ricerca e l'Innovazione Biomedica